Get Premium to unlock powerful stock data
Arcutis Biotherapeutics Inc logo

Arcutis Biotherapeutics Inc

$ 19.53 +1.28 (+7.01%) 10:08 PM EST
P/E:
At Loss
P/B:
3.84
Market Cap:
$ 1.00B
Enterprise V:
$ 672.64M
Volume:
154.24K
Avg Vol (2M):
301.55K
Volume:
154.24K
Market Cap $:
1.00B
PE Ratio:
At Loss
Avg Vol (2-Month):
301.55K
Enterprise Value $:
672.64M
PB Ratio:
3.84
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Arcutis Biotherapeutics Inc
NAICS : 325412 SIC : 2834
3027 Townsgate Road, Suite 300, Westlake Village, CA, USA, 91361
Description
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate, roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
Name Current Vs Industry Vs History
Cash-To-Debt 4.41
Equity-to-Asset 0.7
Debt-to-Equity 0.31
Debt-to-EBITDA -0.34
Piotroski F-Score 2/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 0
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -56.2
3-Year EPS without NRI Growth Rate -56
3-Year FCF Growth Rate -65.7

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 60.14
9-Day RSI 52.26
14-Day RSI 50.77
6-1 Month Momentum % 8.57
12-1 Month Momentum % -16.15

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 10.89
Quick Ratio 10.89
Cash Ratio 10.42

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -40.7
Name Current Vs Industry Vs History
ROE % -65.91
ROA % -56.85
ROIC % -1860.59
ROC (Joel Greenblatt) % -3243.79
ROCE % -59.74

Financials (Next Earnings Date:2022-08-05 Est.)

ARQT's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:ARQT

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0
EPS (TTM) ($) -4.67
Beta 0
Volatility % 61.75
14-Day RSI 50.77
14-Day ATR ($) 1.348878
20-Day SMA ($) 19.731
12-1 Month Momentum % -16.15
52-Week Range ($) 13.59 - 29.37
Shares Outstanding (Mil) 51.42

Piotroski F-Score Details

Component Result
Piotroski F-Score 2
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Arcutis Biotherapeutics Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More